Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of High Risk Renal Tumors
NCT00335556Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jun 2006
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 5
01
Overview
A Phase 2 trial of cyclophosphamide, carboplatin, etoposide, vincristine sulfate liposome injection, pegylated liposomal doxorubicin in Wilms' tumor, clear cell sarcoma of the kidney (CCSK), malignant rhabdoid tumor (MRT), renal cell carcinoma (RCC), sponsored by Children's Oncology Group. Started Jun 2006; status: completed.
02
Drugs
cyclophosphamidecarboplatinetoposidevincristine sulfate liposome injectionpegylated liposomal doxorubicin
03
Conditions
Wilms' tumorclear cell sarcoma of the kidney (CCSK)malignant rhabdoid tumor (MRT)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00335556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335556.